Furthermore, Binimetinib as an MEK1/2 inhibitor could impede the effect of apigenin-induced apoptosis, as well as could restore the expression of Srx by apigenin treatment in cSCC cells. Here, SRXN1 is linked to skin squamous cell carcinoma.